STENTiT B.V.

STENTiT aims to redefine the landscape of endovascular treatments with the Resorbable Fibrillated Scaffold (RFS): a temporary vascular support structure capable of reconstructing the artery to provide better clinical outcomes. The Resorbable Fibrillated Scaffold (RFS) provides a temporary support structure to instantly restore blood flow and aims to facilitate a natural healing response to reconstruct the artery from the inside-out. As a first target indication, we focus on reconstructing the artery for patients suffering from below-the-knee chronic limb-threatening ischemia (CLTI), a pressing issue affecting over 3.5 million patients across the EU and the US. CLTI causes severe blood flow restriction to the foot, which can lead to amputation. The current standard of card, plain old balloon angioplasty (POBA), is highly ineffective, with re-occlusions occurring within 3 to 6 months. Consequently, 250.000 amputations are still performed every year. Disclaimer: The RFS is not for sale and not CE-marked and FDA approved: This implant is an investigational medical device currently in development. The device is not approved or cleared for any indication in any market.